Verve - VERV Expected earnings per share growth for next year

Corporate company logo of Verve Therapeutics Inc. (VERV)

Verve Therapeutics (VERV) is developing gene-editing methods to combat hypercholesterolemia, which correlates with the company's forward EPS dynamics model. A team of leading geneticists aims for the complete cure of patients, while the lack of profit during test scaling limits growth. The -14.50 indicator shows the current metric value, demonstrating the business's adaptation to tight monetary policy within a sideways trend.

VERV: Verve Therapeutics Inc. Expected earnings per share trend next year 07/04/2022 - 08/09/2025

Verve Therapeutics Inc. - analytical breakdowns and key metrics (VERV)

- stock quotes and analyst forecast:
Basic company analysis:VERV, vervetx.com
Core merchandise of Verve Therapeutics, Inc.

This indicator is calculated as the arithmetic mean of analyst forecasts for earnings per share changes in the coming year, reflecting market expectations regarding business scaling rates. For Verve Therapeutics (VERV), which develops gene editing for cardiovascular pathologies, the trend in market expectations for EPS growth serves as a barometer of investor confidence in the commercial success of its innovative drugs.

Who Verve Therapeutics competes with